You are here

Articles

Posted on Thursday, October 3, 2019 - 12:50pm
Patients who maintained MR4.5 at 24 months of consolidation therapy proceeded to discontinuation of nilotinib.
Posted on Thursday, October 3, 2019 - 12:42pm
We demonstrate that combining asciminib with ATP site TKIs enhances target inhibition and suppression of resistant outgrowth in Ph+ clinical isolates and cell lines.
Posted on Thursday, October 3, 2019 - 12:06pm
Dasatinib, a potent Bcr‐Abl tyrosine kinase inhibitor, is approved for the treatment of chronic‐phase chronic myeloid leukemia (CML‐CP) in the frontline and salvage settings.
Posted on Thursday, October 3, 2019 - 11:55am
Chronic myeloid leukaemia is driven by a hybrid gene, BCR-ABL1, that codes for a leukemogenic tyrosine kinase (TK) protein of 210 KDa (p210BCR-ABL1).
Posted on Friday, August 9, 2019 - 10:59am
Jorge Cortes sees the future of CML care in earlier treatments.
Posted on Monday, July 15, 2019 - 4:46pm
Chronic Myeloid Leukaemia Patient Day Saturday, 21st September 2019, Leeds Agenda 9.30 – 10.00  Registration CML and its Treatment
Posted on Saturday, July 6, 2019 - 11:14am
Videos and PDF copies of presentations from the CML Advocates conference, 2019, are now available and can be found by following the link below:
Posted on Saturday, June 29, 2019 - 9:21pm
CML Patient Group at King's College on 24th July 2019. Details below.
Posted on Wednesday, June 26, 2019 - 10:42am
BACKGROUND: All studies of treatment-free remission (TFR) in patients with chronic myeloid leukaemia have discontinued tyrosine kinase inhibitor (TKI) treatment abruptly and have focussed on patients...
Posted on Tuesday, May 28, 2019 - 12:26pm
CML Horizons Conference Lisbon PortugalMay 17th - 19th 2019Nigel Deekes, as the CML Support Group’s conference delegate, describes  highlights from this year’s conference.
Posted on Wednesday, March 27, 2019 - 4:27pm
Latest NCCN guidelines for management of CML include protocols for TKI discontinuation.  Article here:
Posted on Monday, March 18, 2019 - 3:39pm
Up to 80% of CML patients using tyrosine kinase inhibitors (TKIs) reports muscle complaints.
Posted on Thursday, January 31, 2019 - 9:18pm
The World Health Organisation (WHO) recently released an alert about batches of ponatinib (Iclusig) that are not authentic.